ASCO: Brain Irradiation Fends Off Metastases in Small Cell Lung Cancer
CHICAGO -- Prophylactic cranial irradiation after chemotherapy significantly reduces the risk of brain metastasis and doubles one-year survival in small-cell lung cancer (SCLC), a Dutch oncologist reported here.
CHICAGO, June 2 -- Prophylactic cranial irradiation after chemotherapy significantly reduces the risk of brain metastasis and doubles one-year survival in small-cell lung cancer (SCLC), a Dutch oncologist reported here.
SCLC patients who exhibited any response to chemotherapy and then received prophylactic whole-brain irradiation had a 14.6% rate of symptomatic brain metastases at one year compared with 40.4% for those not getting radiation (P
"Prophylactic cranial irradiation significantly reduces the risk of symptomatic brain metastases and significantly prolongs survival," said Dr. Slotman. "This prophylactic irradiation is well tolerated and does not adversely influence quality of life. Prophylactic cranial irradiation should now routinely be offered to all responding SCLC patients with extensive disease."
Dr. Slotman said in an interview that the radiation fends off symptomatic brain metastases by destroying micrometastases that have already taken up residence in the brain. The lesions are too small to detect by brain imaging but provide the genesis for malignant growth. Unfortunately, the benefits of prophylactic whole-brain irradiation do not extend beyond SCLC to the much more common non-small cell lung cancer, he added.
A U.S. oncologist familiar with the study but not involved in it agreed that prophylactic brain irradiation should become the standard of care. He also predicted that U.S. physicians will not be hesitant to adopt the therapy.
"I expect prophylactic cranial irradiation will be taken up quickly in the U.S., as well," commented Roy Herbst, M.D., of the University of Texas M. D. Anderson Cancer Center in Houston. "I think this will take standards of care to a new level."
3 Reasons Urology Practices Should Add Onsite UTI PCR Labs Under New LCD Rules
March 11th 20251. ONSITE PCR TESTING BRINGS SIGNIFICANT CLINICAL BENEFITS TO A PRACTICE. - ACCURACY Traditional urine cultures can give false-negative results. - SPECIFICITY Accurate microbial identification leads to targeted treatment. - SPEED Same day results vs. 3-5 days for traditional urine cultures - - - ANTIBIOTIC RESISTANCE MARKERS Improves antimicrobial stewardship 2. MAINTAIN INDEPENDENCE BY INCREASING REVENUE SIGNIFICANTLY THROUGH REVENUE SHIFTING FROM THE REFERENCE LAB TO THE PRACTICE. - Turnkey: Consultation on COLA and CLIA certification, all necessary equipment, standard operating procedures, personnel sourcing and interview, billing and coding training, 3-4 days of onsite training. - Stark Law Compliant: Complies with anti-kickback statutes. - Medicare part B pays at 100%, Med Advantage Plans at 80% - No lab build-out, only 8 linear feet of counter space needed - Z-code procurement for required states 3. BETTER PATIENT CARE LEADS TO BETTER OUTCOMES. - CONVENIENCE Point of care, no third-party referral lab. - TIMELY Results early in the care process. - CORRECT MEDICATION Avoids two trips to the pharmacy. - BETTER OUTCOMES Reduction of recurrent UTI and hospitalizations
